Steglatro, with a dosage of 15mg, is a medication approved for the treatment of type 2 diabetes. It belongs to a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors [1].
How does Steglatro work to lower blood sugar?
Steglatro (ertugliflozin) works by inhibiting SGLT2, a protein in the kidneys responsible for reabsorbing most of the glucose filtered from the blood back into the bloodstream. By blocking SGLT2, Steglatro reduces this reabsorption, leading to increased excretion of glucose in the urine. This process helps to lower blood glucose levels [1].
What is the recommended Steglatro dosage?
The typical starting dose for Steglatro is 15mg once daily. The dosage may be adjusted by a healthcare provider based on individual patient needs and response [1].
Are there other Steglatro dosages available?
While the question specifies 15mg, other strengths or formulations of Steglatro may exist depending on the market and specific product approvals. Always consult with a healthcare professional or refer to official product information for available dosages [1].
What are the potential side effects of Steglatro?
Common side effects associated with Steglatro can include urinary tract infections, and in men, genital yeast infections. More serious, though less common, side effects can occur. Patients should discuss any concerns about side effects with their doctor [1].
When does the patent for Steglatro expire?
Patent expiry dates for pharmaceutical drugs can be complex, involving multiple patents covering different aspects of the drug, such as composition of matter, method of use, and manufacturing processes. Information regarding specific patent expiry dates for Steglatro can be found through specialized resources like DrugPatentWatch.com [2].
Can generic versions of Steglatro be developed?
Once the relevant patents expire and any periods of market exclusivity end, generic manufacturers may seek approval to market their own versions of Steglatro. This typically leads to increased competition and potentially lower prices for the medication [2].
How does Steglatro compare to other SGLT2 inhibitors?
Steglatro is one of several SGLT2 inhibitors available on the market. Other drugs in this class include empagliflozin (Jardiance), canagliflozin (Invokana), and dapagliflozin (Farxiga). While they share the same mechanism of action, they may differ in their specific efficacy, safety profiles, and cardiovascular or renal benefits observed in clinical trials [1].
What clinical trials have been conducted for Steglatro?
Steglatro has undergone various clinical trials to establish its safety and efficacy in treating type 2 diabetes. These trials have assessed its impact on glycemic control, as well as its effects on cardiovascular outcomes and kidney function, often in combination with other diabetes medications [1].
---
1. Steglatro (ertugliflozin). https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209403s006lbl.pdf
2. DrugPatentWatch.com. https://drugpatentwatch.com/